Evidence map›Paper›PMID 27001753›Full record

ArticleBMC infectious diseases2016

Predictors of opportunistic illnesses incidence in post combination antiretroviral therapy era in an urban cohort from Rio de Janeiro, Brazil.

Lara E Coelho, Sandra W Cardoso, Rodrigo T Amancio, Ronaldo I Moreira, Sayonara R Ribeiro, Alessandra B Coelho, Dayse P Campos, Valdiléa G Veloso, Beatriz Grinsztejn, Paula M Luz

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Observational
  5. Article
  6. Article
  7. Article
  8. Article
  9. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Lara E CoelhoInstituto de Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Avenida Brasil 4365, Manguinhos, CEP: 21045-900, Rio de Janeiro, Brazil. lara.coelho@ini.fiocruz.br.
Sandra W CardosoInstituto de Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Avenida Brasil 4365, Manguinhos, CEP: 21045-900, Rio de Janeiro, Brazil.
Rodrigo T AmancioInstituto de Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Avenida Brasil 4365, Manguinhos, CEP: 21045-900, Rio de Janeiro, Brazil.
Ronaldo I MoreiraInstituto de Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Avenida Brasil 4365, Manguinhos, CEP: 21045-900, Rio de Janeiro, Brazil.
Sayonara R RibeiroInstituto de Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Avenida Brasil 4365, Manguinhos, CEP: 21045-900, Rio de Janeiro, Brazil.
Alessandra B CoelhoInstituto de Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Avenida Brasil 4365, Manguinhos, CEP: 21045-900, Rio de Janeiro, Brazil.
Dayse P CamposInstituto de Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Avenida Brasil 4365, Manguinhos, CEP: 21045-900, Rio de Janeiro, Brazil.
Valdiléa G VelosoInstituto de Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Avenida Brasil 4365, Manguinhos, CEP: 21045-900, Rio de Janeiro, Brazil.
Beatriz GrinsztejnInstituto de Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Avenida Brasil 4365, Manguinhos, CEP: 21045-900, Rio de Janeiro, Brazil.
Paula M LuzInstituto de Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Avenida Brasil 4365, Manguinhos, CEP: 21045-900, Rio de Janeiro, Brazil.
Fundação Oswaldo Cruz · BRInstituto Evandro Chagas · BR

Funding

CCASAnet: Caribbean, Central and South America NetworkU01AI069923 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Pedro Enrique Cahn, Jessica L Castilho · 2006 to 2026
$41.6M
The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit (FioTrials)UM1AI069476 · NIAID · FUNDACAO OSWALDO CRUZ · PI BEATRIZ GRINSZTEJN · 2012 to 2026
$26.3M
NIAID NIH HHS U01 AI069923NIAID NIH HHS U01AI069923NIAID NIH HHS UM1 AI069476
6 · The paper itself

Abstract

backgroundOpportunistic illnesses still account for a huge proportion of hospitalizations and deaths among HIV-infected patients in the post combination antiretroviral therapy (cART) era, particularly in middle- and low-income countries. The aim of this study was to assess predictors of the top four most incident opportunistic illnesses (tuberculosis, esophageal candidiasis, cerebral toxoplasmosis and Pneumocystis jiroveci pneumonia) in an HIV clinical cohort from a middle-income country in the post cART era.

methodsA total of 2835 HIV infected participants aged ≥ 18 years at enrollment were followed from January 2000 to December 2012 until the occurrence of their first opportunistic illness, death or end of study, whichever occurred first. Extended Cox proportional hazards regression models, stratified by use of cART, were fitted to assess predictors of opportunistic illness incidence during follow-up.

resultsThe incidence rates of tuberculosis, esophageal candidiasis, cerebral toxoplasmosis and Pneumocystis jiroveci pneumonia were 15.3, 8.6, 6.0, 4.8 per 1000 persons-year, respectively. Disease specific adjusted Cox models showed that presence of an opportunistic illness at enrollment significantly increased disease incidence while higher nadir CD4+ T lymphocyte count had a significant protective effect in patients not in use of cART. Duration of cART use also significantly reduced disease incidence.

conclusionsOur findings show that, still in the post-cART era, prevention of opportunistic infections can be achieved by preventing immune deterioration by instituting early use of cART. Interventions focusing on early diagnosis and linkage to care in addition to the prompt initiation of cART are essential to reduce the incidence of opportunistic illnesses among HIV infected patients in post-cART era.

Indexed as

AdolescentAdultAIDS-Related Opportunistic InfectionsAntiretroviral Therapy, Highly ActiveBrazilCandidiasisCD4 Lymphocyte CountCohort StudiesFemaleHospitalizationHumansIncidenceMaleMiddle AgedMorbidityPneumonia, PneumocystisAcquired immunodeficiency syndromeAIDS-related opportunistic infectionsCohort studyCox proportional hazards regression modelsHIVIncidence

Identifiers

PMID27001753
PMCPMC4802913
OpenAlexW2305921790

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.